The German Federal Government asked domestic vehicle manufacturers to produce medical equipment, such as masks and ventilators, to help fight Covid-19.
In a statement, the Volkswagen Group announced 20 March it will be providing about 200,000 category FFP-2 and FFP-3 protective face masks for public health protection in the near future. The donation is being made in close cooperation with Federal Minister of Health Jens Spahn.
A spokesperson said the company has more than 125 industrial 3-D printers which could be repurposed to make respirators or other necessary devices, once they receive the required info.
Kathrin Schnurr, spokesperson for Daimler AG Human Resources and External Affairs Communications told International Hospital: “We have inquiries from the medical technology sector. We are currently examining how we can contribute, for example by providing 3D printers or our production expertise.
“In addition, we are in constant communication with the authorities about how and where we can help, for example to sustain the supply infrastructure.”
This follows a trend across Europe as companies unrelated to the medical-device industry offer to retool factories to help make equipment to combat the shortage of devices such as respirators and face masks.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:38Vehicle manufacturers retool to help medical device industry cope with demand
There’s an app for just about everything these days. Now thanks to a new treatment option offered at the University of Minnesota, there’s now one for cancer. These new technologies, known as digital medicines are allowing doctors to monitor their patients, even after they leave the hospital. University of Minnesota Health and Fairview Health Services are the first in the world to apply digital medicines to cancer care. “When we give people chemotherapy in the clinic with an intravenous drug, we’re able to assess the dose and timing and make sure they’re well enough to continue getting the treatment,” said University of Minnesota Physicians oncologist/hematologist Edward Greeno, MD, a professor at the University of Minnesota Medical School’s Department of Medicine in an interview with the Washington Post. “But when you send them home with a bottle of pills, you don’t know when they’re taking them or if they’re well enough to take them.” Dr. Greeno, who also directs the oncology service line for University of Minnesota Health, told the Star Tribune, “the technology could significantly improve cancer care because the timing and dosage of chemo-therapy is critical.” Dr. Greeno, along with other doctors at the Masonic Cancer Clinic at the University of Minnesota Health Clinics and Surgery Center, have begun prescribing pills embedded with small, ingestible sensors. The sensors, designed by Proteus Digital Health, are only the size of a grain of sand, but can track a wealth of information that is helpful for doctors including heart rate, activity level and sleep cycle. Once the pill is ingested, it sends the data to a small patch on the patient’s abdomen, which then connects to a mobile app that both the patient and their doctor can access. This new technology will allow doctors to ensure patients are taking their medications as prescribed. Physicians can automatically tell how many pills a patient has left in their prescription, which helps them better manage refills and potentially save money for the patient. The technology can also give a sense of comfort to some patients, helping them take a more active role in managing their medication. Digital medicine technology has been used to help patients manage medications for a variety of diseases, including diabetes and hypertension, but never before in cancer.
University of Minnesota
https://tinyurl.com/y3tgrga4
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:42New digital pills allow doctors to monitor patients at home
An observational study conducted in a French hospital showed that human contact was responsible for 90 percent of the spread of one species of antibiotic-resistant bacteria to new patients, but less than 60 percent of the spread of a different species. Audrey Duval of the Versailles Saint Quentin University and Institut Pasteur in Paris, France, and colleagues present these findings. People treated in hospitals and other healthcare settings are increasingly at risk of infection with multidrug-resistant bacteria. Many of these microbes produce enzymes called extended-spectrum β-lactamases (ESBLs), which make them resistant to antibiotics. Understanding how ESBL bacteria spread from person to person is key to developing effective prevention strategies. In the new study, Duval and colleagues distributed wearable sensors to hundreds of patients and healthcare workers in a French hospital. Equipped with RFID tags, the sensors allowed the researchers to track patterns of human contact between patients over an eight-week period. Meanwhile, they systematically screened patients for ESBL-producing Escherichia coli and Klebsiella pneumonia. “By combining digital epidemiology and rapid microbiological diagnostic tools, we may be entering a new era to understand and control the risk of hospital-acquired infection with multidrug-resistant bacteria,” Duval says. An observational study conducted in a French hospital showed that human contact was responsible for 90 percent of the spread of one species of antibiotic-resistant bacteria to new patients, but less than 60 percent of the spread of a different species. Audrey Duval of the Versailles Saint Quentin University and Institut Pasteur in Paris, France, and colleagues present these findings in PLOS Computational Biology. People treated in hospitals and other healthcare settings are increasingly at risk of infection with multidrug-resistant bacteria. Many of these microbes produce enzymes called extended-spectrum β-lactamase (ESBLs), which make them resistant to antibiotics. Understanding how ESBL bacteria spread from person to person is key to developing effective prevention strategies. The scientists found that 90 percent of the spread of ESBL K. pneumonia to new patients could be explained by direct or indirect contact with patients who had the same bacteria within the previous eight weeks; this figure was less than 60 percent for ESBL E. Coli. The findings suggest that contact-prevention strategies — primarily hand hygiene — can be very efficient in limiting transmission of ESBL K. pneumonia. However, additional measures, such as environmental decontamination or using antibiotics more appropriately, may be necessary to prevent spread of ESBL E. Coli. The researchers suggest that the same kind of wearable-sensor analysis could be extended to other multidrug-resistant species. Investigation of more detailed genomic data could further illuminate how ESBL-producing bacteria spread. “By combining digital epidemiology and rapid microbiological diagnostic tools, we may be entering a new era to understand and control the risk of hospital-acquired infection with multidrug-resistant bacteria,” Duval says.
ScienceDailyhttps://tinyurl.com/yxbspjca
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:46Human contact plays role in spread of some hospital infections, but not others
FUJIFILM is displaying its evolving portfolio of medical informatics and Enterprise Imaging innovations, by presenting REiLI, Artificial Intelligence (AI) Medical Imaging initiative at HIMSS & Health 2.0 Conference from 11th to 13th June, at Messukeskus Helsinki, Expo & Convention Centre, Helsinki, Finland. It’s transformative time in medicine practice, and FUJIFILM is at the side of the medical world to reengineer imaging strategy. At HIMSS & Health 2.0 Conference 2019, Helsinki, Finland, discover how to design digital diagnostic data hubs delivering “total imaging care” that will benefit patients and physicians. At the booth #6D1, our experts will show the latest innovations from our enterprise imaging portfolio and how they can help you:
Providing a complete picture of each patient’s health so that doctors across the care continuum can make more-informed decisions.
Understanding how an artificial intelligence platform can help impact patient care, improve workflows, and drive new research.
Building and implement an enterprise imaging strategy to reduce the cost of care and impact patient outcomes.
The AI revolution is underway, in an increasingly complex healthcare environment with larger datasets and rising demand for high quality care, Fujifilm, under the REiLI brand, is developing an open platform to realize a new diagnostic imaging workflow. REiLI fits perfectly with our latest release Synapse 5: the server-side-rendering technology and the centralized processing of Synapse 5 allow the easy application of the Artificial Intelligence technology within the normal workflow management tool to support of health professionals. The new open platform will not only host Fujifilm’s AI technologies, but will also host various other AI technologies from external partners. We will strive to support our customers’ by combining diverse AI technologies offering them the best support for their daily work which is currently increasing due to the sheer volume of Imaging scans as well as the complexity of the diseases their patients are facing The Fujifilm Healthcare IT platform Synapse displayed at HIMSS will include our comprehensive medical informatics and enterprise-imaging portfolio: SYNAPSE 5 (PACS) sets a new standard for enterprise imaging. With a focus on speed and interactivity, Synapse 5 PACS provides remarkable on-demand access to massive datasets and the ability to immediately interact with the data. SYNAPSE VNA (vendor-neutral archive) was designed for true imaging interoperability to enable practitioners to provide enhanced patient care across the enterprise. The VNA provides secure, easy-to-manage storage and access to the complete patient imaging record and links all HIT systems. SYNAPSE Enterprise Viewer uses the latest server-side rendering technology to stream imaging securely and quickly to any authorized user. It can be used within applications, directly from your EHR, or on our mobile device apps. Both within and outside of the Enterprise, giving access to imaging immediately and helping clinicians making the most informed and accurate decisions. Synapse Enterprise Viewer allows multiple users to view images simultaneously, and to take control of them as they are presented in real time, thereby improving speed, efficiency and patient care. SYNAPSE 3D is Fujifilm’s portfolio of clinical modules (currently 55) for advanced processing and analysis of the medical imaging: it is a state of the art system which provides powerful and complete tools not only for Oncology, Radiology and Cardiology Departments, but also supports the Clinical and Surgical workflow. Fast, reliable and accurate, based on our heritage of Excellence in Imaging (across, our Photography, Graphics, Film and other mature business domains) Image Intelligence Fujifilm technology, Synapse 3D is the software platform that fully meets the new requirements for advanced processing and displaying of clinical and diagnostic imaging and for oncology and surgical planning. SYNAPSE CWM, Clinical Workflow Manager, is the most advanced Information System on the market today, covering Radiology, Endoscopy and multiple Screening services – Breast, Bowel, AAA and many others. It continues to evolve to support the unique imaging and information needs in today’s busy imaging departments. One platform can support acute care facilities, imaging centers, and radiology practices providing distributed diagnosis. SYNCRO-DOSE is Fujifilms Radiation Dose Index Monitoring system, compliant with European Union Directive 2013/59 / EURATOM. Syncro-Dose is a comprehensive system for monitoring and managing patient radiation exposure at enterprise level across different imaging modalities and hospital facilities. It is a support for the optimization of radiological procedures and acquisition protocols, a tool for supporting clinical audit and it provides a comprehensive Patient Dosimetric History. NEVER STOP… Innovating Healthcare Fujifilm launched Fuji Computed Radiography (FCR), becoming the first company in the world to offer a digital X-ray diagnostic imaging system. Fujifilm saw the opportunity to leverage the technologies it had developed for FCR and contribute to the evolution of connectivity within and among medical facilities. What made Fujifilm’s SYNAPSE concept different was that it used the emerging Internet and web technologies instead of private networks. It was, in essence, a Web-based PACS: the first in the world in 1999 SYNAPSE’s rapid rate of adoption was due in large part to its capability, to contribute significantly to the quality of medical care by delivering images to clinicians fast and securely. We have over 800 Synapse sites in Europe, and over 5000 Synapse systems are installed in healthcare facilities around the world, earning the largest market share worldwide. (*): Fujifilm’s artificial intelligence software is a work in progress and is not commercially available in Europe. (**) Fujifilm estimation based on a set of data from multiple market research studies (***) Synapse 3D is also known as Synapse Vincent is some global markets (Red Dot Award was given to Synapse Vincent) Experts and product specialists are available at Fujifilm booth for product demonstration and to create tailor-made solutions for any healthcare provider.
FUJIFILM Healthcare IT booth: #6D1
https://synapse.fujifilm.eu/index.html
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:51Fujifilm Medical IT shows at HIMSS 2019 how artificial intelligence is driving the future of healthcare
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
